TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10521964
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg every 6 hours
Study: 10521964
Drug: Omeprazole 80
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 80 mg every 12 hours
Study: 1685793
Drug: Suriclone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suriclone (0.1 mg tid)
Study: 1685793
Drug: Suriclone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suriclone (0.2 mg tid)
Study: 1685793
Drug: Suriclone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suriclone (0.3 mg tid)
Study: 1685793
Drug: Suriclone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suriclone (0.4 mg tid)
Study: 1685793
Drug: Diazepam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (5 mg tid)
Study: 29847468
Drug: Ketamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (1 to 2 mg/kg)
Study: 29847468
Drug: Methohexital (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexital (1 to 2 mg/kg)
Study: 31687205
Drug: Nebivolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5 mg/day)
Study: 1729814
Drug: Metoprolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50 mg/day)
Study: 14700340
Drug: 25% EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% EDTA gel applied for 15 seconds
Study: 14700340
Drug: 25% EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% EDTA gel applied for 1 minute
Study: 14700340
Drug: 25% EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% EDTA gel applied for 3 minutes
Study: 10965426
Drug: Topical dexpanthenol
Normalized name: dexpanthenol Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexpanthenol
Study: 29070025
Drug: Daylight photodynamic
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daylight photodynamic therapy (DL-PDT) with methyl aminolevulinate (MAL), 5 treatments over 18 months, with daylight exposure for 2 hours after MAL application.
Study: 26312936
Drug: Triclabendazole (TCBZ)
Normalized name: triclabendazole
DrugBank: Triclabendazole (DB12245)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triclabendazole (TCBZ) 7.5mg/kg administered in two doses with a 12-hour interval (Group I)
Study: 26312936
Drug: Triclabendazole (TCBZ)
Normalized name: triclabendazole
DrugBank: Triclabendazole (DB12245)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triclabendazole (TCBZ) 10mg/kg administered as a single dose (Group II)
Study: 21632810
Drug: Oral ergocalciferol
Normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ergocalciferol (50,000 IU)
Study: 19629889
Drug: Intravenous PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PUFA (100 mg fish oil/kg body weight/day)
Study: 19629889
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (100 mg soya oil/kg body weight/day)
Study: 19629889
Drug: Intravenous PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PUFA
Study: 11829208
Drug: Amisulpride at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride at a dose of 100 mg/day
Study: 7803945
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with bendroflumethiazide (2.5 mg/day, with possible doubling of dosage)
Study: 7803945
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with lisinopril (2.5 mg/day, with possible doubling of dosage)
Study: 7803945
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with slow release diltiazem (120 mg/day, increasing to 240 mg/day if required)
Study: 3190040
Drug: High-dose cyclosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclosporin A (10 mg/kg body weight.d)
Study: 3190040
Drug: Low-dose cyclosporin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporin A (1 mg/kg.d)
Study: 28499440
Drug: Extended Brief
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended Brief Intervention (EBI) - five weekly sessions and one follow-up at 8 weeks
Study: 16580422
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) 20 mg three times a day for 4 weeks
Study: 11134120
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (exact dosage not specified)
Study: 11134120
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake (1000 mg difference)
Study: 9172848
Drug: Psychosocial factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial factors (higher state anxiety, lower anger outward, more past life events, lower expectations of future life events) in nonactive medication group (n = 263)
Study: 31118595
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no testosterone treatment)
Study: 29347887
Drug: Cryo-assisted tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryo-assisted tumor resection en bloc with peritumoral tracer injection (blue dye)
Study: 29347887
Drug: Palliative tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative tumor cryoablation in situ with intratumoral tracer injection (blue dye)
Study: 28153938
Drug: CTRL+DS (unrestricted
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTRL+DS (unrestricted breathing with 0.6-l dead space)
Study: 28153938
Drug: CWS+DS (chest
Approvals — FDA: no, EMA: no, PMDA: no
Description: CWS+DS (chest wall strapping with 0.6-l dead space)
Study: 19403954
Drug: Red Bull
Normalized name: acid red 35
DrugBank: Pantothenic acid (DB01783)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red Bull Energy Drink (ED; 2.0 g taurine, 1.2 g glucuronolactone, 160 mg caffeine, 54 g carbohydrate, 40 mg niacin, 10 mg pantothenic acid, 10 mg vitamin B6, and 10 microg vitamin B12)
Study: 17985956
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sustained release morphine
Study: 12043868
Drug: 2.5% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% sodium hypochlorite and Glyde File Prep applied at the end of the preparation with sterile paper points (group D)
Study: 12043868
Drug: Physiological solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological solution (group A)
Study: 11928421
Drug: Implant retained
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant retained overdentures (IRD)
Study: 7667819
Drug: Aspirin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (200 mg thrice daily, with meals)
Study: 7667819
Drug: Triflusal (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal (300 mg thrice daily, with meals)
Study: 28202786
Drug: Sulpiride (dopaminergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (dopaminergic antagonist)
Study: 24498023
Drug: Bromocriptine (dopaminergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (dopaminergic agonist)
Study: 25799193
Drug: Ground fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ground fish (952 mg of elemental calcium)
Study: 25799193
Drug: Limestone (920
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limestone (920 mg of elemental calcium)
Study: 16728218
Drug: Sirolimus-eluting stent
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus-eluting stent (SES) implantation followed by treatment for restenosis with bare metal stent implantation, balloon dilatation, or intravascular brachytherapy; 82% received bare metal stent implantation, 13.5% balloon dilatation, and 4.5% intravascular brachytherapy.
Study: 16176337
Drug: Antihypertensive medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antihypertensive medicines
Study: 12939217
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of hypoxic gas mixture corresponding to an altitude of 4500 m (controls)
Study: 12939217
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of hypoxic gas mixture corresponding to an altitude of 2500 m (CAD patients)
Study: 2075121
Drug: Pirenzepine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (50 mg p.o.)
Study: 6973987
Drug: Fluproquazone 200
Normalized name: proquazone
DrugBank: Proquazone (DB13649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluproquazone 200 mg
Study: 6973987
Drug: Fluproquazone 100
Normalized name: proquazone
DrugBank: Proquazone (DB13649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluproquazone 100 mg
Study: 31166961
Drug: Ticlopidine/Ginkgo biloba
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine/Ginkgo biloba extract combination drug (Yuclid)
Study: 28368352
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin (3 mg, group M) twice daily
Study: 28368352
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin (3 mg, group M)
Study: 26186658
Drug: Roxithromycin in
Normalized name: Product containing roxithromycin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin in crushed tablet form (n=10)
Study: 26186658
Drug: Roxithromycin in
Normalized name: Product containing roxithromycin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin in conventional tablet form (n=10)
Study: 10732318
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg, Metoclopramide 5 mg, Domperidone 10 mg
Study: 8615482
Drug: Hemodilution (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodilution (6 and 12 mL/kg isovolemic exchange of blood for 6% hydroxyethyl starch)
Study: 23972577
Drug: APAP 650
Normalized name: APAP 650 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: APAP 650 mg
Study: 29671255
Drug: Topical Diquafosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Diquafosol Tetrasodium (3% DQS)
Study: 26777769
Drug: DGG +
Normalized name: Dapagliflozin and Glimepiride
Approvals — FDA: no, EMA: no, PMDA: no
Description: DGG + Ozone Therapy (OT)
Study: 24525659
Drug: AZD2624 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2624 40 mg
Study: 15624096
Drug: Pioglitazone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (3 weeks treatment)
Study: 7583806
Drug: Subcutaneous infusion
Normalized name: subcutaneous infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infusion (SC) of 1000 mL of 5% glucose solution containing 4 g NaCl over 6 hours
Study: 7583806
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion (IV) of 1000 mL of 5% glucose solution containing 4 g NaCl over 6 hours
Study: 7583806
Drug: Both SC
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both SC and IV infusions
Study: 2179286
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg od)
Study: 2179286
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg od)
Study: 19579197
Drug: Non-polymer treatment
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-polymer treatment during surgery
Study: 19579197
Drug: Non-polymer treatment
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-polymer treatment
Study: 19579197
Drug: Polymer treatment
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymer treatment
Study: 15262187
Drug: Prenyl transferase
Normalized name: prenylamine
DrugBank: Prenylamine (DB04825)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenyl transferase inhibitors (in vitro)
Study: 11254825
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg intravenous pamidronate every 3 months + 1 g calcium daily
Study: 11254825
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g calcium daily
Study: 9567053
Drug: Pharmacotherapy for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy for the prevention of recurrence of unipolar affective disorders
Study: 8313786
Drug: Cisplatin intrahepatic
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin intrahepatic arterial infusion (24 mg/m2/day, bolus) plus systemic intravenous 5-fluorouracil (250, 375, or 500 mg/m2/day)
Study: 8313786
Drug: Cisplatin continuous
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin continuous infusion (24 mg/m2/day) plus systemic intravenous 5-fluorouracil (250, 375, or 500 mg/m2/day)
Study: 3049338
Drug: Hydrochlorothiazide 200
Normalized name: labetalol/hydrochlorothiazide 200-25MG ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 200 mg/day
Study: 3049338
Drug: Hydrochlorothiazide (varied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (varied doses)
Study: 18296027
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of methylprednisolone injected into the masseter muscle
Study: 18296027
Drug: No intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intramuscular corticoid (control group)
Study: 11113722
Drug: Valsartan titrated
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan titrated to 160 mg b.i.d.
Study: 9196156
Drug: gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine 1,000 mg/m2 weekly x 7 followed by 1 week of rest, then weekly x 3 every 4 weeks thereafter
Study: 9196156
Drug: fluorouracil (5‐FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fluorouracil (5‐FU) 600 mg/m2 once weekly
Study: 7505354
Drug: Pinacidil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil (25 mg)
Study: 8653729
Drug: Quinidine (330
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (330 mg)
Study: 3987800
Drug: i.v. infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusions of adriamycin (short: 3.00 min)
Study: 3987800
Drug: i.v. infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusions of adriamycin (prolonged: 45 min‐16 h)
Study: 3987800
Drug: i.v. infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusions of adriamycin
Study: 3277903
Drug: Natural progesterone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural progesterone, 100 mg 2 times daily
Study: 3277903
Drug: Tamoxifen, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen, 10 mg 2 times daily
Study: 31799996
Drug: Brimonidine gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine gel, 0.33%
Study: 28639366
Drug: Real-time video
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time video feedback of their own back during massage treatment
Study: 25800891
Drug: Vorinostat 300
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 300 mg twice daily on specified days of a 21-day cycle
Study: 17075501
Drug: Nutrilarm capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrilarm capsules, twice a day for 6 months
Study: 17075501
Drug: Placebo capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, twice a day for 6 months
Study: 7750023
Drug: Sustained-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release formulation B
Study: 7750023
Drug: Sustained-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release formulation C
Study: 7750023
Drug: Nonsustained-release reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsustained-release reference preparation A
Study: 6107768
Drug: IGIV‐maltose (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGIV‐maltose (5% solution in 10% maltose)
Study: 27491607
Drug: Intramyocardial CD34(+)
Normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial CD34(+) cell administration
Study: 27491607
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control (IM placebo injections)
Study: 15259924
Drug: TENS therapy
Normalized name: Walgreens Electronic TENS Therapy Pain Relief Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS therapy for 20 minutes
Study: 15259924
Drug: No TENS
Approvals — FDA: no, EMA: no, PMDA: no
Description: No TENS therapy (control group)
Study: 10904661
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for three days
Study: 10904661
Drug: Antibiotics without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics without examination of the urine
Study: 10904661
Drug: Treatment by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment by telephone for women with earlier episodes of UTI
Study: 9273209
Drug: Subcutaneous Epo
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous Epo (2000 U, twice weekly)
Study: 9273209
Drug: Intravenous Epo
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Epo (156 +/- 57 U/kg/week to 205 +/- 105 U/kg/week, thrice weekly)
Study: 6354441
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of ifosfamide (with mesna), methotrexate (or 5-FU), and vinblastine (protocol I)
Study: 6354441
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of adriamycin and vincristine (protocol II)
Study: 30418217
Drug: Balanced hydroxyethyl
Normalized name: Hydroxyethyl Cellulose
DrugBank: Hydroxyethyl cellulose (DB11602)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced hydroxyethyl starch solution (colloid)
Study: 30418217
Drug: Balanced crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced crystalloid solution (crystalloid)
Study: 30618445
Drug: Three-dose sulphadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose sulphadoxine-pyrimethamine (SP)
Study: 25268398
Drug: Multiple-injection technique
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-injection technique (group M)
Study: 25268398
Drug: Single-injection technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection technique (group S)
Study: 15763607
Drug: Lumiracoxib 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 100 mg QD
Study: 15763607
Drug: Lumiracoxib 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 100 mg QD with loading dose
Study: 9892252
Drug: D-cycloserine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine, 50 mg/d
Study: 1425861
Drug: Intensified oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified oral nutrition with nutrition education, daily dietician visits, and food intake records.
Study: 1425861
Drug: Ad libitum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad libitum nutritional intake during the whole tumour therapy.
Study: 1425861
Drug: Intensified oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified oral nutrition.
Study: 22730816
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide suspension (1 mg twice daily) via transnasal inhalation for one week
Study: 22730816
Drug: Budesonide nasal
Normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide nasal spray (256 microg twice daily)
Study: 15847949
Drug: Gentamycin-steroid combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamycin-steroid combination (GM-S) eardrops
Study: 7841356
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (ferrous sulphate drops: 3 mg/Kg/day)
Study: 28679643
Drug: Intralesional GM‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional GM‐CSF (500 mcg standard dose)
Study: 22751755
Drug: Pharmacist‐assisted medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist‐assisted medication reconciliation, inpatient pharmacist counseling, low‐literacy adherence aids, and individualized telephone follow‐up after discharge
Study: 12907530
Drug: Specific expiratory
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific expiratory muscle training (SEMT), daily, six times a week, 1/2 hour per session for 3 months
Study: 10472466
Drug: Non-buffered saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-buffered saline solution
Study: 10472466
Drug: Buffered saline
Normalized name: Phosphate Buffered Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered saline solution (pH 8)
Study: 8979657
Drug: Medication alarm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication alarm device (TimeCap)
Study: 8979657
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication alarm device (Control)
Study: 17619868
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine (10 mg)
Study: 6378733
Drug: Antacids and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids and/or anticholinergic drugs
Study: 29573330
Drug: Tinzaparin 175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin 175 IU kg-1 once daily
Study: 29573330
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target INR of 2.0-3.0)
Study: 22863206
Drug: Qigong training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qigong training (level 1 Chaoyi Fanhuan Qigong, CFQ), given over three half‐days, followed by weekly review/practice sessions for eight weeks, with home practice for 45 to 60 minutes per day.